Poet is like a Pharma Company in phase III with a huge portfolio what is waiting for the FDA approval. Read this, change "pharma" by "POET", Novartis by Apple, J&J by Google, and so on. and think about possible POET´s partnership, finantial model, purchasing low-risk options, etc.
http://www.mckinsey.com/insights/health_systems_and_services/new_frontiers_in_pharma_r_and_38d_investment
Any differences??
GLTA